within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AB14_Valganciclovir;
model Valganciclovir 
   extends Pharmacolibrary.Drugs.ATC.J.J05AB14;

  annotation(Documentation(
    info ="<html><body><p>Valganciclovir is an oral prodrug of ganciclovir, an antiviral agent used to treat cytomegalovirus (CMV) infections, particularly in immunocompromised patients such as organ transplant recipients and those with HIV/AIDS. It is currently approved and widely used for CMV prophylaxis and treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (median age 26 years), following a single oral dose of valganciclovir, under fasting conditions.</p><h4>References</h4><ol><li><p>Nguyen, T, et al., &amp; Hirt, D (2021). Population Pharmacokinetics of Intravenous Ganciclovir and Oral Valganciclovir in a Pediatric Population To Optimize Dosing Regimens. <i>Antimicrobial agents and chemotherapy</i> 65(3) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02254-20&quot;>10.1128/AAC.02254-20</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33318012/&quot;>https://pubmed.ncbi.nlm.nih.gov/33318012</a></p></li><li><p>Suganuma, E, et al., &amp; Oh-Ishi, T (2021). Efficacy, safety, and pharmacokinetics of oral valganciclovir in patients with congenital cytomegalovirus infection. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 27(2) 185–191. DOI:<a href=&quot;https://doi.org/10.1016/j.jiac.2020.08.019&quot;>10.1016/j.jiac.2020.08.019</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32907793/&quot;>https://pubmed.ncbi.nlm.nih.gov/32907793</a></p></li><li><p>Tängdén, T, et al., &amp; Pea, F (2018). Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens. <i>Clinical pharmacokinetics</i> 57(11) 1399–1405. DOI:<a href=&quot;https://doi.org/10.1007/s40262-018-0638-5&quot;>10.1007/s40262-018-0638-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29546589/&quot;>https://pubmed.ncbi.nlm.nih.gov/29546589</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Valganciclovir;
